Answers are grounded in this paper and cite their sources.
Background A novel live-attenuated yellow fever (YF) vaccine candidate, vYF, is currently in development. Previous studies in non-human primates (NHPs) have evaluated its safety, immunogenicity, and efficacy. To further characterize the immune response, this study assessed the breadth and magnitude of neutralizing antibodies (NAbs) induced by vYF. Methods Immunogenicity was evaluated in NHPs across multiple parameters, including NAb titers against the vaccinal virus strain from 14 to 258 days post-vaccination. The breadth of neutralization was assessed using a panel of four YF virus strains selected to represent diverse phylogeny, isolation dates, and geographic origins. Titers from vYF-vaccinated NHPs were compared with those from YF-VAX–vaccinated NHPs. Two additional control strains, Stamaril ® (current vaccine) and the wild-type parent strain Asibi, were included. Amino acid (AA) sequences of viral envelope residues associated with known neutralizing epitopes were analyzed to explore potential correlates with neutralization profiles. Results NAb titers from vYF-vaccinated NHPs were comparable to those obtained with the Asibi strain for two of the four wild-type strains, and 0.3 to 0.5 Log lower for the remaining two. All wild-type strains were neutralized with titers at least 3-fold higher than the established correlate of protection, indicating a broad neutralization profile. Neutralization patterns were similar between vYF- and YF-VAX–vaccinated NHP sera. Conclusion This study adds to the evidence that the vYF may elicit the same breadth of neutralizing antibody responses in NHPs, than YF-VAX reference vaccine.
No takes yet. Share an insight, caveat, or question.
Girerd-Chambaz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: